vs
伯乐实验室（BIO）与CNA FINANCIAL CORP（CNA）财务数据对比。点击上方公司名可切换其他公司
伯乐实验室的季度营收约是CNA FINANCIAL CORP的1.8倍（$693.2M vs $389.0M），伯乐实验室净利率更高（103.9% vs 77.6%，领先26.2%），伯乐实验室同比增速更快（3.9% vs -2.0%），CNA FINANCIAL CORP自由现金流更多（$542.0M vs $119.1M），过去两年伯乐实验室的营收复合增速更高（6.5% vs -2.2%）
美国伯乐实验室是深耕生命科学研究与临床诊断领域的专业技术产品开发商及制造商，1952年由加州大学伯克利分校校友施瓦茨夫妇在伯克利创立，总部位于加州赫拉克勒斯，业务网络覆盖全球。
CNA金融公司是总部位于美国伊利诺伊州芝加哥的金融企业，旗下核心子公司大陆意外伤害保险公司成立于1897年，大陆保险公司的历史则可追溯至1853年，当前母公司CNA于1967年正式注册成立，在保险及金融服务领域拥有深厚的行业积淀。
BIO vs CNA — 直观对比
营收规模更大
BIO
是对方的1.8倍
$389.0M
营收增速更快
BIO
高出5.9%
-2.0%
净利率更高
BIO
高出26.2%
77.6%
自由现金流更多
CNA
多$422.9M
$119.1M
两年增速更快
BIO
近两年复合增速
-2.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $693.2M | $389.0M |
| 净利润 | $720.0M | $302.0M |
| 毛利率 | 49.8% | — |
| 营业利润率 | -17.2% | 97.2% |
| 净利率 | 103.9% | 77.6% |
| 营收同比 | 3.9% | -2.0% |
| 净利润同比 | 200.6% | 1338.1% |
| 每股收益（稀释后） | $26.59 | $1.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOCNA
| Q4 25 | $693.2M | $389.0M | ||
| Q3 25 | $653.0M | $393.0M | ||
| Q2 25 | $651.6M | $398.0M | ||
| Q1 25 | $585.4M | $397.0M | ||
| Q4 24 | $667.5M | $397.0M | ||
| Q3 24 | $649.7M | $401.0M | ||
| Q2 24 | $638.5M | $404.0M | ||
| Q1 24 | $610.8M | $407.0M |
净利润BIOCNA
| Q4 25 | $720.0M | $302.0M | ||
| Q3 25 | $-341.9M | $403.0M | ||
| Q2 25 | $317.8M | $299.0M | ||
| Q1 25 | $64.0M | $274.0M | ||
| Q4 24 | $-715.8M | $21.0M | ||
| Q3 24 | $653.2M | $283.0M | ||
| Q2 24 | $-2.2B | $317.0M | ||
| Q1 24 | $383.9M | $338.0M |
毛利率BIOCNA
| Q4 25 | 49.8% | — | ||
| Q3 25 | 52.6% | — | ||
| Q2 25 | 53.0% | — | ||
| Q1 25 | 52.3% | — | ||
| Q4 24 | 51.2% | — | ||
| Q3 24 | 54.8% | — | ||
| Q2 24 | 55.6% | — | ||
| Q1 24 | 53.4% | — |
营业利润率BIOCNA
| Q4 25 | -17.2% | 97.2% | ||
| Q3 25 | 10.0% | — | ||
| Q2 25 | 11.8% | 95.5% | ||
| Q1 25 | 4.0% | 87.9% | ||
| Q4 24 | 8.7% | 5.3% | ||
| Q3 24 | 9.9% | 90.0% | ||
| Q2 24 | 15.9% | 99.5% | ||
| Q1 24 | 7.3% | — |
净利率BIOCNA
| Q4 25 | 103.9% | 77.6% | ||
| Q3 25 | -52.4% | 102.5% | ||
| Q2 25 | 48.8% | 75.1% | ||
| Q1 25 | 10.9% | 69.0% | ||
| Q4 24 | -107.2% | 5.3% | ||
| Q3 24 | 100.5% | 70.6% | ||
| Q2 24 | -339.2% | 78.5% | ||
| Q1 24 | 62.9% | 83.0% |
每股收益（稀释后）BIOCNA
| Q4 25 | $26.59 | $1.11 | ||
| Q3 25 | $-12.70 | $1.48 | ||
| Q2 25 | $11.67 | $1.10 | ||
| Q1 25 | $2.29 | $1.00 | ||
| Q4 24 | $-25.89 | $0.07 | ||
| Q3 24 | $23.34 | $1.04 | ||
| Q2 24 | $-76.26 | $1.17 | ||
| Q1 24 | $13.45 | $1.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.5B | — |
| 总债务越低越好 | $1.2B | $3.0B |
| 股东权益账面价值 | $7.5B | $11.6B |
| 总资产 | $10.6B | $69.4B |
| 负债/权益比越低杠杆越低 | 0.16× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资BIOCNA
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.6B | — | ||
| Q1 24 | $1.6B | — |
总债务BIOCNA
| Q4 25 | $1.2B | $3.0B | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.2B | $3.0B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BIOCNA
| Q4 25 | $7.5B | $11.6B | ||
| Q3 25 | $6.7B | $11.3B | ||
| Q2 25 | $7.1B | $10.7B | ||
| Q1 25 | $6.7B | $10.3B | ||
| Q4 24 | $6.6B | $10.5B | ||
| Q3 24 | $7.5B | $10.8B | ||
| Q2 24 | $6.8B | $9.9B | ||
| Q1 24 | $9.1B | $9.7B |
总资产BIOCNA
| Q4 25 | $10.6B | $69.4B | ||
| Q3 25 | $9.7B | $69.8B | ||
| Q2 25 | $10.2B | $68.9B | ||
| Q1 25 | $9.5B | $67.3B | ||
| Q4 24 | $9.4B | $66.5B | ||
| Q3 24 | $10.6B | $67.4B | ||
| Q2 24 | $9.7B | $65.2B | ||
| Q1 24 | $12.6B | $65.1B |
负债/权益比BIOCNA
| Q4 25 | 0.16× | 0.26× | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.18× | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $164.9M | $570.0M |
| 自由现金流经营现金流 - 资本支出 | $119.1M | $542.0M |
| 自由现金流率自由现金流/营收 | 17.2% | 139.3% |
| 资本支出强度资本支出/营收 | 6.6% | 7.2% |
| 现金转化率经营现金流/净利润 | 0.23× | 1.89× |
| 过去12个月自由现金流最近4个季度 | $374.6M | $2.4B |
8季度趋势，按日历期对齐
经营现金流BIOCNA
| Q4 25 | $164.9M | $570.0M | ||
| Q3 25 | $120.9M | $720.0M | ||
| Q2 25 | $116.5M | $562.0M | ||
| Q1 25 | $129.9M | $638.0M | ||
| Q4 24 | $124.2M | $703.0M | ||
| Q3 24 | $163.6M | $748.0M | ||
| Q2 24 | $97.6M | $616.0M | ||
| Q1 24 | $69.8M | $504.0M |
自由现金流BIOCNA
| Q4 25 | $119.1M | $542.0M | ||
| Q3 25 | $89.2M | $704.0M | ||
| Q2 25 | $70.8M | $538.0M | ||
| Q1 25 | $95.5M | $620.0M | ||
| Q4 24 | $81.2M | $665.0M | ||
| Q3 24 | $123.4M | $730.0M | ||
| Q2 24 | $55.4M | $597.0M | ||
| Q1 24 | $29.6M | $484.0M |
自由现金流率BIOCNA
| Q4 25 | 17.2% | 139.3% | ||
| Q3 25 | 13.7% | 179.1% | ||
| Q2 25 | 10.9% | 135.2% | ||
| Q1 25 | 16.3% | 156.2% | ||
| Q4 24 | 12.2% | 167.5% | ||
| Q3 24 | 19.0% | 182.0% | ||
| Q2 24 | 8.7% | 147.8% | ||
| Q1 24 | 4.8% | 118.9% |
资本支出强度BIOCNA
| Q4 25 | 6.6% | 7.2% | ||
| Q3 25 | 4.9% | 4.1% | ||
| Q2 25 | 7.0% | 6.0% | ||
| Q1 25 | 5.9% | 4.5% | ||
| Q4 24 | 6.4% | 9.6% | ||
| Q3 24 | 6.2% | 4.5% | ||
| Q2 24 | 6.6% | 4.7% | ||
| Q1 24 | 6.6% | 4.9% |
现金转化率BIOCNA
| Q4 25 | 0.23× | 1.89× | ||
| Q3 25 | — | 1.79× | ||
| Q2 25 | 0.37× | 1.88× | ||
| Q1 25 | 2.03× | 2.33× | ||
| Q4 24 | — | 33.48× | ||
| Q3 24 | 0.25× | 2.64× | ||
| Q2 24 | — | 1.94× | ||
| Q1 24 | 0.18× | 1.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIO
| Clinical Diagnostics | $425.3M | 61% |
| Life Science | $267.9M | 39% |
CNA
暂无分部数据
